1. EFFICACY AND SAFETY OF RECOMBINANT HUMAN ACTIVATED PROTEIN C FOR SEVERE SEPSIS (PROWESS) GORDONR. BERNARD, M.D. et al. The New England Journal of Medicine 2001 Mar 8;344(10):699-709 臺北醫學大學附設醫院 藥劑部 林家宇

2. Introduction Severe sepsis, associated with : –Acute organ dysfunction –Generalized inflammatory –Procoagulant response to an infection The rate of death from 30% to 50% despite advances in critical care

4. Activated protein C / drotrecogin α activated Xigris® (Eli Lilly, Indianapolis) 5mg/vial 24ug/kg/hr, IVD for 96hrs 健保價： 10’184 NT A 60kg adult patient needs to spend 285’152 NT

5. METHODS

6. Randomized, double-blind, placebo controlled trial From July 1998 through June 2000 Multicentre study: 164 centres International: 11 countries Follow-up period: 28 days Outcome: All-cause mortality at day 28

7. Selection Criteria Patients were eligible for the trial if they –Had a known or suspected infection –Within a 24-hour period: 3 or more signs of systemic inflammation At least one organ or system dysfunction

10. Treatment Assignments Block randomization Patients were 1:1 randomly assigned to receive: –Drotrecogin α activated: 24μg/kg/hr for 96 hours –Placebo (0.9% saline with or without 0.1% albumin): IV at a constant rate for 96 hours The study protocol did not call for a standardized approach to critical care (e.g., the use of antibiotics, fluids, vasopressors, or ventilatory support)

11. Evaluation of Patients Patients were followed for 28 days after the start of the infusion or until death Data assessed –Base-line characteristics –D-dimer, IL-6 levels, and microbiologic-culture –Side effect

12. Statistical Analysis The primary efficacy end point was death from any cause and was assessed 28 days after the initiation of the infusion The trial was designed to enroll 2280 patients; two planned interim analyses by an independent data and safety monitoring board occurred after 760 and 1520 patients had been enrolled

13. RESULTS

14. At the time of the second interim analysis of data from 1520 patients, enrollment was suspended because the differences in the mortality rate between the two groups exceeded the a priori guideline for stopping the trial Results presented here include data from additional patients who were enrolled before the completion of the second interim analysis

15. The data from two FDA reports (FDA 2001a and FDA 2001b) made it clear that the trial contained two substudies, one with 720 participants following the initial protocol and a subsequent phase with 970 participants where the registered protocol had been amended.

16. Base-Line Characteristics of the Patients Of 1728 patients who underwent randomization, 1690 received the study drug or placebo All randomized patients were followed for the entire 28 days except for one patient in the drotrecogin alfa activated group who did not receive the study drug This patient was classified as having died on day 28 in the mortality analysis of all randomized patients

20. Approximately 75% of the patients had at least 2 dysfunctional organs or systems at the time of enrollment The lungs and the abdomen infection were the most common (53.6% and 19.9%)(Table 2) The infections of G(+) and G(-) was similar within each group and between the two groups Plasma D-dimer and serum IL-6 levels were elevated in 99.7% and 98.5% of the patients Base-Line Characteristics of the Patients

21. Efficacy 28 days after the start of the infusion, the rate of death (P=0.005): –Placebo group: 259 of 840 (30.8%) –Drotrecogin α activated: 210 of 850 (24.7%)

22. Efficacy

24. A consistent effect of treatment with drotrecogin α activated was observed among the subgroups (data not shown) –APACHE II score –The number of dysfunctional organs or systems –Level of protein C deficiency –Other indicators of the severity of disease Sex Age The site of infection The type of infection : G(+), G(-), or mixed Efficacy

25. IL-6 levels and D-dimer levels were significantly lower in the drotrecogin α activated group Levels of D-Dimer and IL-6

27. Complications The incidence of serious bleeding was higher in the drotrecogin α activated group than placebo (3.5% vs. 2.0%) (P=0.06) Rate of new infections was similar (P=0.85) –Drotrecogin α activated: 25.5% –Placebo: 25.1%

29. DISCUSSION

30. Patients who received drotrecogin α activated had greater decreases in plasma D-dimer levels during the first 7 days after the infusion was initiated, indicating a reduction in the generation of thrombin The rise in D-dimer levels after the completion of the 96-hour infusion of drotrecogin α activated An evaluation of longer periods of infusion of drotrecogin α activated may be warranted (→Cost 2932 NT/hr)

31. Summary Drotrecogin α activated: Decease D-dimer and IL-6 levels Reduce the rate of death: 6.1% 1 additional life would be saved for every 16 patients Bleeding was the most common adverse event 1 additional serious bleeding event would occur for every 66 patients

32. Thanks for your attention